Study of Azacytidine Combined With Lenalidomide As Maintenance Therapy Based on MRD Monitoring in AML
Status:
Recruiting
Trial end date:
2022-09-01
Target enrollment:
Participant gender:
Summary
Great progress has been witnessed on the treatment of acute myeloid leukemia (AML) in recent
years. However, elderly patients ineligible for receiving high dose chemotherapy and
allo-HSCT, have high relapse rate and treatment-related complications. Azacitidine (AZA), a
listed hypomethylating agent in China in 2018, is the only approved demethylating drug in the
treatment of AML, following the NCCN guidelines. In addition, lenalidomide(LEN) has been
shown to rapidly enhance cytotoxic T- and natural killer (NK)-cell function and reduce
relapse post-chemotherapy in patients with MM, also has substantial activity as a single
agent in elderly patients with AML. Measurable residual disease (MRD) has been proven to be
highly prognostic in quite a number clinical studies. This study is aimed to validate the
efficacy and safety advantages of the maintenance therapy that contain AZA and LEN in elderly
or unfit for intensive therapy patients with AML based on MRD monitoring.